Macquarie Group Ltd. Boosts Stake in Pfizer Inc. (PFE)

Macquarie Group Ltd. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 20.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,340,162 shares of the biopharmaceutical company’s stock after buying an additional 4,344,595 shares during the period. Pfizer comprises 1.6% of Macquarie Group Ltd.’s holdings, making the stock its largest position. Macquarie Group Ltd. owned approximately 0.43% of Pfizer worth $919,341,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of PFE. Charles Schwab Investment Advisory Inc. acquired a new position in shares of Pfizer during the 2nd quarter worth about $286,229,000. Dimensional Fund Advisors LP boosted its stake in shares of Pfizer by 15.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 54,233,658 shares of the biopharmaceutical company’s stock worth $1,967,651,000 after buying an additional 7,059,171 shares during the last quarter. Federated Investors Inc. PA boosted its stake in shares of Pfizer by 110.5% during the 2nd quarter. Federated Investors Inc. PA now owns 6,263,587 shares of the biopharmaceutical company’s stock worth $227,243,000 after buying an additional 3,287,377 shares during the last quarter. Jensen Investment Management Inc. acquired a new position in shares of Pfizer during the 2nd quarter worth about $110,291,000. Finally, Natixis boosted its stake in shares of Pfizer by 144.1% during the 2nd quarter. Natixis now owns 2,850,809 shares of the biopharmaceutical company’s stock worth $103,428,000 after buying an additional 1,683,117 shares during the last quarter. Institutional investors own 68.64% of the company’s stock.

A number of equities research analysts have recently issued reports on PFE shares. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Monday, August 6th. Morningstar set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, August 8th. SunTrust Banks upped their target price on shares of Pfizer to $41.00 and gave the company a “hold” rating in a report on Friday, August 10th. Cantor Fitzgerald set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Monday, August 13th. Finally, Deutsche Bank set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, August 21st. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $43.27.

Pfizer stock opened at $45.51 on Friday. The stock has a market capitalization of $267.28 billion, a price-to-earnings ratio of 17.17, a P/E/G ratio of 2.24 and a beta of 0.88. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.47. Pfizer Inc. has a twelve month low of $33.20 and a twelve month high of $45.83.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.03. The firm had revenue of $13.30 billion for the quarter, compared to analysts’ expectations of $13.53 billion. Pfizer had a net margin of 44.63% and a return on equity of 25.26%. The business’s revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.67 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 3 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be issued a $0.34 dividend. The ex-dividend date of this dividend is Thursday, November 8th. This represents a $1.36 annualized dividend and a yield of 2.99%. Pfizer’s dividend payout ratio is currently 51.32%.

In related news, major shareholder Pfizer Inc purchased 55,556 shares of the stock in a transaction on Monday, October 15th. The shares were purchased at an average cost of $18.00 per share, with a total value of $1,000,008.00. Following the acquisition, the insider now directly owns 21,976,484 shares in the company, valued at $395,576,712. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.

WARNING: “Macquarie Group Ltd. Boosts Stake in Pfizer Inc. (PFE)” was published by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/11/30/macquarie-group-ltd-boosts-stake-in-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Recommended Story: What are the most popular ETFs

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply